Stockhead on MSN
Health check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
inews.co.uk on MSN
I’m a urologist, eight changes I made in my 50s to cut my risk of cancer
Dr Marc Laniado made a choice to be more mindful of his own health - here's what he discovered, from 'exercise snacking' to ...
Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...
THOMASVILLE — Archbold Urology is committed to offering patients in the region access to the most advanced treatments for urologic conditions that affect many of its neighbors.
MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...
Let's see what this radiopharmaceuticals company has announced this morning. The post Telix shares jump 14% on big news appeared first on The Motley Fool Australia.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
Nurses and advanced practice registered nurses (APRNs) play a central role in preventive care, screening, chronic disease management, and patient education. Expanding this workforce is particularly ...
The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...
Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...
The news: Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591. Shares ...
Shares rebound from Monday’s $90b wipeout; oil back to $US90 after earlier surge toward $120; Fortescue completes Alta buy; Air New Zealand axes guidance over conflict. Follow live.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results